Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1

Zhang, Meili; Yao, Zhengsheng; Patel, Hiral; Garmestani, Kayhan; Zhang, Zhuo; Talanov, Vladimir S.; Plascjak, P.; Goldman, Carolyn K.; Janik, John E.; Brechbiel, Martin W.; Waldmann, Thomas A.

doi:10.1073/pnas.0702496104

Cited by 29 publications

(13 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17,18 We used this model to determine whether IL-22 levels correlated with tumor burden and prognosis. HeFi-1 monoclonal antibody prolonged survival compared with PBS-treated mice ( Figure 7D), confirming previous studies.…”

Section: Alk ؉ Alcl-derived Cell Lines Express Il-22r1 and Th17-assocmentioning

confidence: 99%

See 1 more Smart Citation

A novel role for IL-22R1 as a driver of inflammation

Savan

McFarland

Reynolds

et al. 2011

Blood

View full text Add to dashboard Cite

The interleukin (IL)-22R1 chain of the heterodimeric IL-22 receptor is not expressed on normal leukocytes, but this receptor is expressed on T cells from anaplastic lymphoma kinase-positive (ALK ؉ ) anaplastic large cell lymphoma (ALCL) patients. To investigate the consequences of aberrant expression of this receptor on lymphocytes, we generated transgenic mice that express IL-22R1 on lymphocytes. The health of these animals progressively deteriorated at 8 to 12 weeks of age, as they displayed respiratory distress, rough coat and sluggish movement, and subsequent lethality due to multiorgan inflammation. The IL-22R1 transgenic animals developed neutrophilia that correlated with increased levels of circulating IL-17 and granulocyte colony-stimulating factor. In addition, these mice had increased serum

show abstract

Section: Alk ؉ Alcl-derived Cell Lines Express Il-22r1 and Th17-assocmentioning

confidence: 99%

“…17,18 Two groups of 10 SCID/NOD mice received intravenous injections of 1 ϫ 10 7 Karpas299. Group 1 received 200 L of PBS on days 7, 14, and 21 after injection of Karpas299.…”

Section: Tumorigenicity Of Karpas299 Cells In Scid/nod Micementioning

confidence: 99%

A novel role for IL-22R1 as a driver of inflammation

Savan

McFarland

Reynolds

et al. 2011

Blood

View full text Add to dashboard Cite

show abstract

“…For example, very encouraging synergy studies with the combination of flavopiridol and the bcl2 antagonist HA14-1 have recently been presented, indicating that the combination displayed early evidence of mitochondrial injury [19] leading to apoptosis. Zhang et al [20] likewise demonstrated increased action in vitro and in vivo of anti-CD25 monoclonal antibodies in the treatment of HTLV1(+) leukemias when combined with flavopiridol.…”

Section: Clinical and Preclinical Efficacy Studiesmentioning

confidence: 91%

Cell Cycle Regulatory Kinase Modulators: Interim Progress and Issues

Sausville¹

2005

CTMC

View full text Add to dashboard Cite

Since a prior review of cell cycle inhibitors developed at the National Cancer Institute, continued progress in the application of these molecules has been pursued. Evidence of preliminary activity on the part of flavopiridol in certain chronic leukemias has pointed to that disease area as of potential interest, but likely by affecting transcriptional regulation through non-cell cycle-related CDKs. Brief duration infusion early phase trials with UCN-01, and combination studies with cytotoxics are commencing. Emerging structural data has refined the basis for screening strategies directed at cell cycle regulatory kinases, including cdks, chk kinases and most recently the mitotic phase aurora kinases. This interval progress report will review and update progress in these related but distinct drug discovery and development interest areas.

show abstract

“…The sensitivity of cHL to radiotherapy provoked interest in anti-CD30 radioimmunoconjugates, most commonly using the radionuclides 131 I and 90 Y. Preclinical studies of 131 Ilabeled Ki-4 (anti-CD30 monoclonal antibody) and 90 Ylabeled HeFi-1 (anti-CD30 antibody) were promising in potency of the radiotherapy [51,52]. In the phase 1 study of 131 I-Ki-4, therapy was temporarily effective but was associated with severe hematologic toxicities [51].…”

Section: Radioimmunoconjugatesmentioning

confidence: 97%

Anti-CD30 Antibodies for Hodgkin Lymphoma

Foyil

Bartlett

2010

Curr Hematol Malig Rep

View full text Add to dashboard Cite

Treatment of refractory or relapsed classical Hodgkin lymphoma (HL) remains challenging, but targeted immunotherapy has recently emerged as a potential treatment option for these patients. Although first-generation monoclonal anti-CD30 antibodies proved disappointing, current efforts to modify anti-CD30 antibodies to improve binding of effector cells and enhance activity appears more promising, as does the development of novel antibody-drug conjugates (ADCs). ADCs offer the potential to deliver potent therapies with minimal toxicity. One highly active ADC, brentuximab vedotin (SGN-35), combines an anti-CD30 monoclonal antibody and the antitubulin agent monomethyl auristatin E. Initial phase 1 studies of brentuximab vedotin showed a 52% overall response rate in relapsed HL, with minimal toxicity. This article highlights the development of anti-CD30 antibodies and ADCs for relapsed or refractory classical HL.

show abstract

Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1

Cited by 29 publications

References 35 publications

A novel role for IL-22R1 as a driver of inflammation

A novel role for IL-22R1 as a driver of inflammation

Cell Cycle Regulatory Kinase Modulators: Interim Progress and Issues

Anti-CD30 Antibodies for Hodgkin Lymphoma

Contact Info

Product

Resources

About